Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Geoffrey Matus"'
Autor:
Martin Boegemann, Sara Khaksar, Guillaume Bera, Alison Birtle, Catherine Dopchie, Louis-Marie Dourthe, Els Everaert, Martin Hatzinger, Dirko Hercher, Werner Hilgers, Geoffrey Matus, Laura Garcia Alvarez, Laurent Antoni, Martin Lukac, Geneviève Pissart, Paul Robinson, Tony Elliott
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice. This st
Externí odkaz:
https://doaj.org/article/bcb68afe464843cda635014d0327f858
Autor:
Els Everaert, M Lukac, Louis-Marie Dourthe, Werner Hilgers, Catherine Dopchie, Dirko Hercher, Geneviève Pissart, Guillaume Bera, Martin Hatzinger, Alison Birtle, Laurent Antoni, Geoffrey Matus, Laura Garcia Alvarez, Paul Robinson, Martin Boegemann, S. Khaksar, Tony Elliott
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
BMC Cancer
BMC Cancer
Background With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice. This study prima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ca290cdbee899fe078424091f2e323e
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/49072
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/49072
Publikováno v:
Experimental Hematology. 30:546-554
Objective Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with prolonged anemia caused by defective erythropoietin (Epo) production. We enrolled 34 recipients of an allogeneic HSCT in three consecutive trials to determine the
Autor:
D. Sheehan, M Lukac, Laura Garcia Alvarez, Dirko Hercher, Geoffrey Matus, Martin Kluska, Martin Hatzinger, Martin Boegemann, Alison Birtle, Laurent Antoni, Els Everaert, Geneviève Pissart, Lu Zou, Catherine Dopchie, L Dearden
Publikováno v:
Journal of Clinical Oncology. 35:239-239
239 Background: In the COU-AA-302 trial, abiraterone acetate plus prednisone (AAP) resulted in extension of radiographic progression-free survival (rPFS) and overall survival in chemotherapy-naïve mCRPC patients compared to prednisone alone. However
Autor:
Geoffrey Matus, Inge M. van Oort, Luis M. Antón Aparicio, Fred Saad, Phillip Parente, Sergio Bracarda, Axel Heidenreich, Mert Basaran, Alexandros Ardavanis, Winald R. Gerritsen, Wito de Schultz, Simon Hitier, Giuseppe Di Lorenzo, Amit Bahl, Zafar Malik
Publikováno v:
Journal of Clinical Oncology. 32:242-242
242 Background: Cbz is an established second-line treatment for pts with mCRPC, having demonstrated an overall survival benefit (with P) vs mitoxantrone with P in the Phase III TROPIC trial. The global CUP (CABAZ_C_05005) and EAP (NCT01254279) (both
Autor:
Axel Heidenreich, Zafar Malik, Fred Saad, Phillip Parente, Simon Hitier, Inge M. van Oort, Geoffrey Matus, Wito de Schultz, Luis M. Antón Aparicio, Sergio Bracarda, Amit Bahl, Alexandros Ardavanis, Winald R. Gerritsen, Giuseppe Di Lorenzo, Mert Basaran
Publikováno v:
Journal of Clinical Oncology. 32:109-109
109 Background: Cbz + P demonstrated an overall survival benefit vs mitoxantrone + P in pts with mCRPC in the Phase III TROPIC trial. The CUP (CABAZ_C_05005) and EAP (NCT01254279) (both funded by Sanofi) were established to allow access to Cbz ahead
Autor:
Phillip Parente, Zafar Malik, Fred Saad, Alexandros Ardavanis, Winald R. Gerritsen, Mert Basaran, Amit Bahl, Simon Hitier, Luis M. Antón Aparicio, Axel Heidenreich, Geoffrey Matus, Inge M. van Oort, Giuseppe Di Lorenzo, Wito de Schultz
Publikováno v:
Journal of Clinical Oncology. 31:5055-5055
5055 Background: Cbz + P provides a significant survival benefit vs mitoxantrone + P in pts with mCRPC (Phase III TROPIC study [NCT00417079]; hazard ratio 0.70; p < 0.0001). These findings supported the initiation of ongoing Sanofi-funded CUP and EAP